Biotech closures drop to ten in 2026, marking improvement after years of high layoffs

Fierce's annual "biotech graveyard" list shows ten company closures reported so far in 2026, a sharp decline from sixteen last year and twenty‑seven in 2023.

The drop reflects broader easing of biotech layoffs after a peak in 2025, while the sector's XBI index has been buoyant and several startups have launched successful IPOs.

The report also notes positive signs such as the FDA's more industry‑friendly stance and the approval of Revolution Medicines' pancreatic cancer therapy Rasonque.

Despite the improving trend, the continued closures remind the industry that challenges remain.